
Apyx Medical Corporation APYX
$ 2.79
-2.11%
Annual report 2025
added 03-10-2026
Apyx Medical Corporation Deferred Revenue 2011-2026 | APYX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Apyx Medical Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 500 K | 900 K | 500 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 900 K | 500 K | 633 K |
Quarterly Deferred Revenue Apyx Medical Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 1.05 M | 853 K | - | - | 759 K | 533 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 M | 533 K | 800 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 11.1 | -0.72 % | $ 314 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.16 | - | $ 1.31 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
3.41 M | $ 3.45 | 3.29 % | $ 129 M | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Cytosorbents Corporation
CTSO
|
182 K | $ 0.61 | -2.42 % | $ 38 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 11.53 | 4.63 % | $ 413 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 57.59 | -2.51 % | $ 3.14 B | ||
|
LENSAR
LNSR
|
2.6 M | $ 5.48 | -1.44 % | $ 65.5 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
Insulet Corporation
PODD
|
14 M | $ 167.53 | -2.25 % | $ 11.8 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.05 | -3.23 % | $ 17.8 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Sintx Technologies
SINT
|
4.72 K | $ 2.42 | - | $ 6.71 M | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 4.82 | -0.52 % | $ 1.02 B | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
TransMedics Group
TMDX
|
2.9 M | $ 94.93 | -2.21 % | $ 3.23 B | ||
|
Tandem Diabetes Care
TNDM
|
9.53 M | $ 19.42 | -2.26 % | $ 1.32 B | ||
|
Globus Medical
GMED
|
27.7 M | $ 90.03 | -0.63 % | $ 12.2 B | ||
|
NanoVibronix
NAOV
|
175 K | - | - | $ 1.08 M | ||
|
Integer Holdings Corporation
ITGR
|
5.21 M | $ 85.85 | 2.26 % | $ 2.98 B | ||
|
Pulmonx Corporation
LUNG
|
18 K | $ 1.27 | -4.51 % | $ 51.7 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.88 | 1.69 % | $ 36.8 M |